Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Asthma
Phase PHASE3
Enrollment 660
Locations 101 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of TQC2731 injection (420 mg Q4W) in adult subjects with inadequately controlled severe asthma. A total of 660 trial participants are expected to be enrolled, with trial participants randomized in a 1:1 ratio to receive either TQC2731 (420 mg Q4W) or placebo (Q4W) via subcutaneous (SC) administration.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: TQC2731 injection — TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.
  • Drug: Placebo — Placebo without drug substance.

Primary Outcomes

  • Annualized incidence of asthma exacerbations (From the first day of dosing to the completion of 52 weeks of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-03-21
Completion: 2028-03
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 660 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Contact Information
Study Contact:
Jinping Zheng, Doctor
18928868238
jpzhenggy@163.com
Qingling Zhang, Doctor
13609068871
zqling68@hotmail.com
Yalin Jiang, Master
15956792887
94613793@qq.com
The People's Hospital of Bozhou
Interventions
  • Drug: TQC2731 injection — TQC2731 injection can specifically bind to the Thymic Stromal Lymphopoietin (TSLP) protein, blocking TSLP-dependent downstream signaling expression in engineered cells and inhibiting the production of inflammatory cytokines.
  • Drug: Placebo — Placebo without drug substance.
Study Locations (101 sites)
The People's Hospital of Bozhou, Bozhou, Anhui 236000 China
Anhui Chest Hoispital, Hefei, Anhui 230022 China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022 China
Lu'an People's Hospital of Anhui Province, Lu'an, Anhui 237000 China
Tongling People's Hospital, Tongling, Anhui 244000 China
Peking University First Hospital, Beijing, Beijing Municipality 100000 China
Beijing No.6 Hospital, Beijing, Beijing Municipality 100007 China
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000 China
Zhangzhou Municipal Hospital of Fujian, Zhangzhou, Fujian 363000 China
The First Hospital of Lanzhou University, Lanzhou, Gansu 730000 China
Eligibility Criteria
Inclusion Criteria: * Sign the informed consent form before the trial to fully understand the purpose, process and possible adverse reactions of the trial; * Age 18 \~ 75 years old, gender is not limited; * Documented physician diagnosis of asthma at least 12 months prior to Visit 1; * Subjects who received high-dose Inhaled Corticosteroids (ICS) in asthma control medications prescribed by their physicians at least 6 months prior to Visit 1; * There must be a record of receiving a stable total daily dose of ICS at least 3 months prior to visit 1; * There must be a record of the use of other asthma control medications at a stable dose at least 3 months prior to visit 1; For subjects taking maintenance oral hormones, the dose of oral hormones is up to 10mg prednisone per day or 20mg every other day (or equivalent) and must be stable for at least 30 days prior to visit 1 and during treatment. * Documented at least 2 asthma exacerbations in the 12 months prior to Visit 1 and no major asthma exacerbation events in the 1 month prior to signing informed. Exclusion Criteria: * Have a clinically significant lung disease other than asthma; * Pre-existing autoimmune disease; * A history of known or suspected immunosuppression, including a history of invasive opportunistic infections; * Any disease that has not been determined to be stable by the investigator; * Cancer history: Patients with basal cell carcinoma, skin localized squamous cell carcinoma, or cervical carcinoma in situ are eligible to be enrolled in this study if they had completed curative therapy for at least 12 months prior to visit 1. Patients with other malignancies who had completed curative treatment for at least 5 years prior to visit 1 could be enrolled in the study. * Current smoker or smoking history ≥10 pack-years (former smokers with smoking history \<10 pack-years had quit smoking less than 6 months before interview 1); * Other factors determined by the investigator that subjects were not suitable to participate in the study.

The Cohort Study for Asthma in China

NCT05937334
Recruiting
Conditions Asthma, Bronchial
Phase Not Applicable
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The study is to establish a standardized asthma cohort study, build an information network platform system and a biospecimen bank for asthma cohort, establish clear follow-up standards and norms, observe the asthma outcomes and identify biomarkers to predict asthma outcomes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Diagnostic Test: lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma — lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma were performed. All interventions was made according to routine diagnosis and treatment.

Primary Outcomes

  • Asthma Control Test(ACT) (2 years)
  • Asthma Control Questionnaire(ACQ) (2 years)
  • Induced sputum analysis (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Chao Yang Hospital
Principal Investigators:
  • Kewu Huang, M.D. (STUDY_DIRECTOR) - Beijing Chao Yang Hospital
Contact Information
Study Contact:
Meishan Liu, M.D.
8613141403749
ccmuliumeishan@163.com
Ying Wang, M.D.
8613426121753
kokosalaki1020@sina.com
Interventions
  • Diagnostic Test: Diagnostic Test: lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma — lung function test, chest CT, induced sputum, blood routine test, IgE test, FeNO test, six minutes walk test, questionnaires for asthma were performed. All interventions was made according to routine diagnosis and treatment.
Study Locations (1 sites)
Beijing Chao Yang Hospital, Beijing, Beijing Municipality China
Eligibility Criteria
Inclusion Criteria: * Age \>18 * Meet the 2023 edition of GINA asthma diagnostic criteria * Subjects must sign informed consent prior to study participation, participate in the study according to the protocol and follow up for 2 years Exclusion Criteria: * Suffering from other massive lung tissue destructive diseases such as severe bronchiectasis and tuberculosis * Severe pleural disease and/or sternal and rib lesions * Serious uncontrolled disease of other system * Thoracic or abdominal surgery in the past 3 months * Eye surgery in the past three months * Retina detachment * Myocardial infarction within the last 3 months * Hospitalized for heart disease within the past 3 months * Ongoing anti-tuberculosis treatment * Pregnancy or breast feeding
Conditions Healthy Participants
Phase PHASE1
Enrollment 28
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The trial is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of AMG 691 in healthy Chinese and Japanese participants

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Drug: AMG 691 — AMG 691 will be administered subcutaneously

Primary Outcomes

  • Maximum Observed Serum Concentration (Cmax) of AMG 691 (Day 1 up to Day 154)
  • Area Under the Serum Concentration Time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUC0-t) of AMG 691 (Up to Day 154)
  • Area Under the Serum concentration Time Curve from Time Zero to Infinity (AUC0-inf) of AMG 691 (Up to Day 154)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-08-07
Completion: 2027-03-31
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: true
Enrollment: 28 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amgen
Principal Investigators:
  • MD (STUDY_DIRECTOR) - Amgen
Contact Information
Study Contact:
Amgen Call Center
866-572-6436
medinfo@amgen.com
Interventions
  • Drug: AMG 691 — AMG 691 will be administered subcutaneously
Study Locations (1 sites)
PPD - Las Vegas Research Unit, Las Vegas, Nevada 89113 United States
Eligibility Criteria
Inclusion Criteria: * Healthy male or female participants, 18 to 60 years of age. * First-generation Chinese ancestry (born in China, Hong Kong, Taiwan, or Macau with 2 Chinese parents and 4 Chinese grandparents) or first-generation Japanese ancestry (born in Japan with 2 Japanese parents and 4 Japanese grandparents). * Body mass index (BMI) 18.0 to 30.0 kg/m\^2 (inclusive) and body weight ≥40 kg. * In good general health based on medical history, physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory evaluations. * Female participants must not be pregnant or breastfeeding. * Participants of reproductive potential must agree to follow protocol-specified contraception requirements. * Willing to maintain usual diet and physical activity regimen throughout study participation. Exclusion Criteria: * Clinically significant medical condition, disease, or abnormal finding that could interfere with study participation or interpretation of results. * Clinically significant ECG abnormalities * Clinically significant abnormal blood pressure or pulse rate at screening/check-in. * History of malignancy (except adequately treated in situ cervical cancer or non-melanoma skin cancer \>5 years before dosing). * Deep vein thrombosis or pulmonary embolism within 3 months prior to check-in. * History of hypersensitivity/anaphylaxis to biologic therapies, mammalian-derived products, or AMG 691 excipients. * Active, chronic, recurrent, or unresolved infection; history of severe infection requiring intravenous (IV) antibiotics within the past 3 years. * Positive or indeterminate QuantiFERON-TB Gold test. * Untreated or unresolved helminth parasitic infection. * History of immunodeficiency. * Receipt of live or live-attenuated vaccines within 12 weeks before check-in or planned during the study. * Estimated glomerular filtration rate (eGFR) \<70 mL/min/1.73 m\^2. * Alanine Aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, or direct bilirubin \>1.5 × Upper Limit Normal (ULN). * Positive screening tests for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection. Hepatitis B serology consistent with prior vaccination is permitted. * Use of prohibited prescription, over-the-counter, herbal, vitamin, or dietary supplement products within 30 days (or 5 half-lives) before enrollment, unless approved by the investigator. * History of illicit drug use within 1 year, positive drug screen, or unwillingness to abstain from illicit drugs/cannabinoids during the study. * Use of tobacco or nicotine-containing products within 6 months prior to check-in. * History of alcohol abuse or excessive alcohol consumption. * History of non-suicidal self-injury within 5 years or unstable major depressive disorder/other severe psychiatric disorder within 2 years. * Participation in another investigational drug study within 90 days (or 5 half-lives) prior to check-in. * Previous exposure to AMG 691. * Recent donation of blood, plasma, or platelets. * Any participant considered unsuitable by the investigator or unwilling to comply with study restrictions.
Conditions Asthma in Children
Phase NA
Enrollment 112
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is the most common chronic lung disease in children. It affects more than 1 in 10 children in France. The methacholine bronchial challenge test (MBT) is indicated to assess the probability of asthma suggested by clinical symptoms by measuring the forced expiratory volume in one second (FEV1), after inhalation of a cumulative dose of methacholine. In children, the measurement of FEV1 requires a high level of cooperation from the child, which can be the source of false negatives or no result if this is not obtained. The objective of this study is to evaluate if the measurement of the respiratory function by the forced oscillations technique, allows to predict the variation of the FEV1 obtained

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Procedure: Airway Oscillation System — After each methacholine dose administred, respiratory function will be measured by forced oscillation

Primary Outcomes

  • Change in lung impedance measurement (During the procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-07
Completion: 2027-02-06
Eligibility
Age: 6 Years – 16 Years
Sex: ALL
Volunteers: false
Enrollment: 112 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Montpellier
Principal Investigators:
  • Stefan MATECKI, MD (PRINCIPAL_INVESTIGATOR) - Montpellier Univerty Hospital
Contact Information
Study Contact:
Stefan MATECKI, MD
+33 4 67 33 59 12
Stephan.matecki@umontpellier.fr
Anne REQUIRAND
a-requirand@chu-montpellier.fr
Anne Requirand
a-requirand@chu-montpellier.fr
CHU de Montpellier
Interventions
  • Procedure: Airway Oscillation System — After each methacholine dose administred, respiratory function will be measured by forced oscillation
Study Locations (1 sites)
CHU de Montpellier, Montpellier, France
Eligibility Criteria
Inclusion Criteria: * Age between 6 and 16 years * FEV1 \> 60% * Child referred to the pulmonary function test laboratory for a non-specific bronchial hyperactivity test with methacholine * Child under treatment with inhaled corticosteroids stopped for at least 3 weeks * Oral consent from the child and at least one of the legal representatives * Child affiliated or benefiting from a social security plan Exclusion Criteria: * Use of a short-acting beta-adrenergic bronchodilator within the last 6 hours or anticholinergic bronchodilator within the last 12 hours * Use of a long-acting beta-adrenergic bronchodilator (licensed for use in children) in the past 36 hours * Upper or lower respiratory tract infections within 3 weeks prior to inclusion * Epilepsy under treatment * Subject's participation in another interventional study that may alter respiratory function * Patient unable to give consent, vulnerable
Conditions Pediatric Asthma
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This pilot study aims to explore whether a digital approach to managing childhood asthma using connected inhalers and video consultations triggered by alerts from these devices - could work as well as standard in-person care. The connected inhalers track when children use their daily prevention medication and their rescue medication for asthma symptoms. If a child misses several days of prevention medication or uses their rescue inhaler frequently, their doctor receives an alert and can schedule a video consultation to adjust their treatment. Fifty children aged 4-12 years with asthma will participate for 8 months, with half using this digital system and half receiving usual care. The study will measure whether this new approach is practical and acceptable to families and doctors, and will look at its effects on asthma control, quality of life, and healthcare use. The results will help design a larger study to fully test if this digital approach could improve asthma care for children.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Active telemonitoring using real-time data from digital inhalers. — Telemonitoring system relying on the use of 2 digital inhalers FindAir ONE for pMDI,one for the controller the other for the reliever treatment. Active telemonitoring using real-time data from digital inhalers Investigators will be alerted by email if a child: * fails to take his or her controller treatment for 4 continuous days and/or * uses \> 4 doses of reliever treatment over 24 hours * uses \< 12 doses of reliever treatment over 3 months (indication to decrease the controller treatment). For alert (2), a teleconsultation will be scheduled within 2 working days to assess and adapt treatment as needed. Emergency treatment may be adjusted for approximately one week. Alerts within the following 7 days will be considered part of the same clinical episode. For alerts (1) and (3), a teleconsultation will be scheduled within 7 working days to assess and adapt management as needed.Spirometry and pulse oximetry if needed.
  • Other: Standard — Standardized care + passive recording of asthma treatment use (controller and reliever treatments) using digital inhalers

Primary Outcomes

  • Change in asthma severity measured by the Composite Asthma Severity Index (CASI) (At the inclusion visit (baseline) and 8 months (+/- 1 month) (end of study) in each group)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-25
Completion: 2027-07
Eligibility
Age: 4 Years – 12 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Principal Investigators:
  • David DUMMOND, MD, PhD (PRINCIPAL_INVESTIGATOR) - Hôpital Necker Enfants Malades AP-HP
Contact Information
Study Contact:
David DUMMOND, MD, PhD
01 87 89 20 28
david.drummond@aphp.fr
sarah BOUCHARD, Project manager
01 42 19 28 79
sarah.bouchard@ahp.fr
David DUMMOND, MD, PhD
01 87 89 20 28
david.drummond@aphp.fr
Hôpital Necker Enfants Malades AP-HP
Interventions
  • Device: Active telemonitoring using real-time data from digital inhalers. — Telemonitoring system relying on the use of 2 digital inhalers FindAir ONE for pMDI,one for the controller the other for the reliever treatment. Active telemonitoring using real-time data from digital inhalers Investigators will be alerted by email if a child: * fails to take his or her controller treatment for 4 continuous days and/or * uses \> 4 doses of reliever treatment over 24 hours * uses \< 12 doses of reliever treatment over 3 months (indication to decrease the controller treatment). For alert (2), a teleconsultation will be scheduled within 2 working days to assess and adapt treatment as needed. Emergency treatment may be adjusted for approximately one week. Alerts within the following 7 days will be considered part of the same clinical episode. For alerts (1) and (3), a teleconsultation will be scheduled within 7 working days to assess and adapt management as needed.Spirometry and pulse oximetry if needed.
  • Other: Standard — Standardized care + passive recording of asthma treatment use (controller and reliever treatments) using digital inhalers
Study Locations (1 sites)
Hôpital Necker Enfants Malades AP-HP, Paris, 75015 France
Eligibility Criteria
Inclusion Criteria: * Aged 4 to 12, whose asthma has been diagnosed by a physician * Followed up for their asthma by a pediatrician or pediatric pulmonologist * With asthma severity corresponding to GINA grades 2, 3 or 4 (Global Asthma Initiative Guidelines) * Whose controller and reliever treatments are administered using pressurized metered-dose inhalers (p-MDIs) * With social security * Whose parents or legal guardian(s): * Have given their written and informed consent for their child's participation and their participation, * Have a smartphone in the household that can download the application and is compatible with it, * Are capable, in the opinion of the investigator, of understanding the use of the mobile application and module FRENCH CARE specifically dedicated to the research and the digital inhalers provided. Non-inclusion Criteria: * Patients with another pathology that could interfere with the evaluation of the endpoints (e.g, bronchopulmonary dysplasia, cystic fibrosis, etc.) * Patients whose parents or legal representative(s) are, in the opinion of the investigator, unable to understand the purpose of the study and/or express their consent. * Patients benefiting from State Medical Aid Exclusion Criteria: \- Patient who did not use the system within 15 days of the inclusion visit
Conditions Depression
Phase Not Applicable
Enrollment 35
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Despite experiencing higher rates of depressive symptoms (Center for Disease Control and Prevention, 2020) and similar rates of Major Depressive Disorder (MDD; Substance Abuse and Mental Health Services Administration (SAMHSA), 2019), Latino adolescents in the U.S. are significantly less likely than their non-Latino White peers to receive treatment for MDD (SAMHSA, 2019). The purpose of this study is to identify a stakeholder-preferred implementation strategy that may improve psychotherapy attendance among Latino adolescents. Latino adolescent-parent dyads and healthcare providers will be recruited from healthcare settings and social media. Focus groups will be conducted with healthcare providers (n=5), and individual interviews will be conducted with Latino adolescents with a diagnosis of depression (n=15) and their parents (n=15).

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Primary Outcomes

  • Preferred implementation strategy to improve depression treatment use generated from qualitative interviews/focus groups (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-10-13
Completion: 2026-12-30
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: true
Enrollment: 35 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Principal Investigators:
  • Allison M Stafford, PhD (PRINCIPAL_INVESTIGATOR) - Duke University School of Nursing
Contact Information
Study Contact:
Allison M Stafford, PhD
(317) 498-7333
allison.stafford@duke.edu
Norma Garcia Ortiz
919-684-9331
norma.garcia.ortiz@duke.edu
Allison M Stafford, PhD
Researchmatch.org
Interventions
N/A
Study Locations (1 sites)
Researchmatch.org, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria for Teens: * Male gender * Aged 13-17 years * Diagnosed with Major Depressive Disorder or Persistent Depressive Disorder * Referred to psychotherapy and/or prescribed antidepressant medications for depression Exclusion Criteria for Teens: * Experiencing imminent thoughts of self-harm or suicide * Experiencing acute psychological distress (e.g., uncontrolled crying) Inclusion Criteria for Parents: * Parent or legal guardian of teen * Able to read and speak English or Spanish Exclusion Criteria for Parents: * Unable to read/speak English or Spanish Inclusion Criteria for Healthcare Providers: * Self-identification as regularly providing clinical care to Latino adolescents with depression * Be in a role in which they can provide or refer patients to depression treatment Exclusion Criteria for Healthcare Providers * Unable to provide or refer to depression treatment
Conditions Depression - Major Depressive Disorder
Phase NA
Enrollment 200
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to identify patient subgroups who are most likely to benefit from escitalopram, thereby promoting individualized and precision treatment for depression. This multicenter, prospective, single-arm intervention study will enroll 200 adults aged 18-65 years with major depressive disorder, who will receive escitalopram oxalate oral solution for 8 weeks. Depressive symptoms, cognitive function, and adverse events will be assessed at baseline, during treatment, and after 8 weeks of treatment to evaluate efficacy and safety. Escitalopram blood concentrations will be measured at week 4 to monitor treatment adherence and support safety evaluation. Through comprehensive data collection and multimodal analysis, this project seeks to clarify the biological mechanisms of escitalopram and provide evidence to guide more precise clinical use of antidepressant therapy.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Escitalopram (Oral antidepressant) — Participants will receive escitalopram oral solution as open-label monotherapy.

Primary Outcomes

  • Change from baseline in Hamilton Depression Rating Scale (HAMD) (Week 4 and 8 of treatment duration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-20
Completion: 2026-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University
Collaborators: The First Hospital of Hebei Medical University, First Hospital of China Medical University, Shandong Mental Health Center, Hebei Provincial Mental Health Center
Contact Information
Study Contact:
Weihua Yue
86-010-82805307
dryue@bjmu.edu.cn
Tong Yu
86-010-82805307
tongyu@bjmu.edu.cn
Weihua Yue
010-82805307
dryue@bjmu.edu.cn
Peking University Sixth Hostipal
Interventions
  • Drug: Escitalopram (Oral antidepressant) — Participants will receive escitalopram oral solution as open-label monotherapy.
Study Locations (5 sites)
Peking University Sixth Hostipal, Beijing, Beijing Municipality 100191 China
Hebei Provincial Mental Health Center, Baoding, Hebei 071000 China
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei 050031 China
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001 China
Shandong Mental Health Center, Jinan, Shandong 250014 China
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-65 years (including 18 and 65), no gender restriction, Han Chinese ethnicity. 2. Meets the diagnostic criteria for depressive disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), confirmed by the Mini-International Neuropsychiatric Interview, version 5.0 (MINI). 3. Outpatients or inpatients; Hamilton Depression Rating Scale-17 items (HAMD-17) score ≥17; Hypomania Checklist-32 (HCL-32) score ≤13; and Clinical Global Impressions-Severity (CGI-S) score ≥4. 4. First depressive episode (duration ≤3 months), with no use of antidepressants or other psychotropic medications in the past 3 months. 5. Written informed consent obtained from the patient. Exclusion Criteria: 1. Meet DSM-IV diagnostic criteria other mental disorders, including schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive disorder, etc.. 2. Individuals with intellectual disabilities or who are unable to cooperate for other reasons, or those lacking or having incomplete civil capacity during the onset of illness; 3. Suffering from neurological or organic brain diseases (such as stroke, cerebral hemorrhage, brain tumors, Parkinson's disease, epilepsy, etc.) and a history of severe traumatic brain injury; 4. Have attempted suicide within the past 3 months, or currently present a high suicide risk, defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) item 10 score ≥5. 5. Are pregnant or breastfeeding, cannot use reliable contraception during the study, or plan to conceive (or impregnate a partner) within 3 months after study initiation. 6. Have known allergies to escitalopram oxalate or its excipients. 7. Are currently taking medications that may interfere with the evaluation of escitalopram efficacy. 8. Have participated in another drug clinical trial within the past 3 months. 9. Have contraindications to MRI scanning, such as metal implants or claustrophobia. 10. Considered unsuitable for study participation by the investigators for any other reason.
Conditions HIV Antiretroviral Therapy (ART) Adheren...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Prevention of mother-to-child transmission (PMTCT) of HIV virtually eliminates transmission of HIV from mothers to their infants. Adherence to PMTCT (i.e., to antiretroviral therapy, infant prophylaxis, and exclusive breastfeeding) during pregnancy and the postpartum period is challenging, with evidence from sub-Saharan Africa (SSA) showing suboptimal adherence and persistent viremia among perinatal women. Perinatal depression (PD) is a major driver of women's poor adherence to PMTCT. Interventions that involve male partners to provide social and food/economic support could be a promising approach for addressing PD and PMTCT, yet few interventions have intervened with couples to improve systems of support, communication, and other dyadic processes. The investigators propose to develop and test a couple-based approach to intervene on the mother's perinatal depressive symptoms and to strengthen the relationship and support system for partners to work together around depression to improve PMTCT adherence. The study will take place in antenatal and HIV care settings in Zomba, Malawi. The specific aims are: (1) to develop a couple-based intervention to target perinatal depression (PD) based on an evidence-based approach using problem-solving therapy (PST), augmented with content on couple communication and problem-solving skills; and (2) to assess the feasibility and acceptability (F\&A) of the intervention via a pilot randomized controlled trial (RCT). Our short-term goal is the produce a couple-focused PST intervention that can be added to the global health toolkit for treating depression in perinatal women. Our long-term goal is to produce a high-impact and sustainable intervention leveraging the couple relationship that can be scaled-up to address depression, PMTCT adherence, and family health.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Couples Problem Solving Therapy — A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.

Primary Outcomes

  • Participation in the intervention (following the intervention period, an average of 5 months)
  • Retention (through study completion, an average of 11 months)
  • Intervention fidelity (following the intervention period, an average of 5 months)
  • Acceptability (Assessed at the 3-month post-partum follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-11
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: National Institute of Mental Health (NIMH), Invest in Knowledge Initiative (IKI) - Zomba, Malawi
Principal Investigators:
  • Amy Conroy, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
James Mkandawire, MPH
+265(0) 999412756
James3mkandawire@gmail.com
Amy Conroy, Ph.D.
1 303 522 9439
amy.conroy@ucsf.edu
James Mkandawire, MPH
Invest in Knowledge (IKI)
Interventions
  • Behavioral: Couples Problem Solving Therapy — A couples-based problem solving program to deal with depression, PMTCT adherence, and couple communication.
Study Locations (1 sites)
Invest in Knowledge (IKI), Zomba, Malawi
Eligibility Criteria
Inclusion Criteria: * In a marriage or cohabitating union for at least 6 months. * One member of the couple is a woman in the second or third trimester of pregnancy who is living with HIV and screens positive for depression (\>10 on the PHQ9). * Have revealed their HIV status to their partner if living with HIV\> Exclusion Criteria: * Fear their safety would be at risk. * Report incidents of severe intimate partner violence (IPV) in the past three months using the WHO IPV measure.
Conditions Erectile Disfunction, Coronary Artery Di...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to assess changes in patients' erectile function after percutaneous coronary intervention (PCI) using a standard IIEF (International Index of Erectile Function) questionnaire at 1, 3, and 6 months post-PCI. By doing this, we try to compare patients' responses to PCI after having a heart attack and stable angina to see the real effect of myocardial infarction on erectile function status in the long term by comparing it with a very similar group.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Change in erectile function score after percutaneous coronary intervention (PCI) (Baseline (post-recovery from PCI) to 6 months follow-up])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-15
Completion: 2026-11
Eligibility
Age: 30 Years – 75 Years
Sex: MALE
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kırıkkale University
Principal Investigators:
  • Timucin Sipal, Assistan Prof (PRINCIPAL_INVESTIGATOR) - Kirikkale Univerity faculty of medicine department of Urology
  • Caglar Alp, Assistant Prof (STUDY_DIRECTOR) - Kirikkale Univerity Faculty of Medicine department of Cardiology
Contact Information
Study Contact:
Timucin Sipal, MD, PhD
+905338170659
drtimucin@hotmail.com
Caglar Alp, MD, PhD
+905054013070
drcaglaralp@gmail.com
Timucin Sipal, MD, PhD
+905338170659
drtimucin@hotmail.com
The Hospital of Kirikkale Univerity Faculty of Medicine
Interventions
N/A
Study Locations (1 sites)
The Hospital of Kirikkale Univerity Faculty of Medicine, Kirikkale, 71450 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria * Male patients aged 30-75 years * Undergoing successful percutaneous coronary intervention (PCI) for one of the following: * Acute myocardial infarction (Group 1) * Stable angina (Group 2) * Hemodynamically stable after the PCI procedure * Survival of the index hospitalization * Ability to provide written informed consent * Sexually active within the 3 months prior to enrollment * Willingness and ability to complete follow-up visits and questionnaires at: * Baseline (post-PCI recovery) * 3 months * 6 months Exclusion Criteria * Known malignancy (active or recently treated) * Neurological disorders affecting erectile function, including: * Spinal cord injury * Multiple sclerosis * Parkinson's disease * Uncontrolled diabetes mellitus (HbA1c \> 9%) * Presence of more than two chronic systemic diseases, such as: * Severe renal disease * Severe hepatic disease * Severe pulmonary disease * Polypharmacy, defined as chronic use of more than three daily medications * Absence of sexual activity or lack of a sexual partner * Refusal or inability to provide informed consent or complete study questionnaires * Severe psychiatric illness interfering with study participation * Endocrine disorders, including: * Untreated hypogonadism * Thyroid disease * Major post-PCI complications preventing participation, including: * Reinfarction * Stroke * Heart failure

One-Day cTBS Over the Precuneus

NCT07758010
Recruiting
Conditions Depressive Disorder, Treatment-Resistant...
Phase NA
Enrollment 69
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn whether two forms of one-day accelerated transcranial magnetic stimulation (TMS) can reduce depressive symptoms in adults with treatment-resistant depression. Treatment-resistant depression is depression that has not improved enough after at least two adequate antidepressant medication treatments. TMS is a non-invasive treatment that uses magnetic pulses to stimulate specific areas of the brain. The main questions this study aims to answer are: * Does continuous theta-burst stimulation (cTBS) targeting the precuneus reduce depressive symptoms 4 weeks after treatment compared with sham stimulation? * Does intermittent theta-burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex reduce depressive symptoms 4 weeks after treatment compared with sham stimulation? Researchers will compare precuneus cTBS, left dorsolateral prefrontal cortex iTBS, and sham stimulation to determine whether either active treatment reduces depressive symptoms more than sham stimulation. Participants will be randomly assigned to one of the three groups and will not be told which treatment they initially receive. Participants will: * Complete screening procedures and baseline assessments of depression, rumination, and cognitive function * Receive 20 sessions of active or sham TMS during one in-person study day * Complete follow-up assessments 1, 2, 3, and 4 weeks after the intervention * Report any side effects or medical problems experienced during the study Participants initially assigned to sham stimulation may choose to receive active TMS after completing the 4-week follow-up period. Those who choose this option will receive either precuneus cTBS or left dorsolateral prefrontal cortex iTBS and will complete additional follow-up assessments.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Precuneus-targeted continuous theta-burst stimulation — Active continuous theta-burst stimulation is delivered to the Pz location of the international 10-20 EEG system to target the precuneus. Stimulation is administered with a double-cone coil at 80% of the participant's resting motor threshold. Each session consists of 600 pulses delivered over approximately 40 seconds. Participants receive 20 sessions during a single day, for a total of 12,000 pulses, with session onsets separated by approximately 30 minutes. If 80% of resting motor threshold is not tolerated, the intensity may be reduced to the highest tolerable level.
  • Device: Left dorsolateral prefrontal cortex intermittent theta-burst stimulation — Active intermittent theta-burst stimulation is delivered to the left dorsolateral prefrontal cortex. The stimulation target is identified using the Beam F3 method. Stimulation is administered with a figure-of-eight coil at 80% of the participant's resting motor threshold. Each session consists of 600 pulses delivered over approximately 3 minutes. Participants receive 20 sessions during a single day, for a total of 12,000 pulses, with session onsets separated by approximately 30 minutes. If 80% of resting motor threshold is not tolerated, the intensity may be reduced to the highest tolerable level.
  • Device: Sham transcranial magnetic stimulation — Sham transcranial magnetic stimulation is administered at the left dorsolateral prefrontal cortex location identified using the Beam F3 method. A figure-of-eight coil is inverted so that the active surface faces away from the scalp. The stimulator is operated at 80% of the participant's resting motor threshold using the same intermittent theta-burst timing and approximate session duration as the active left dorsolateral prefrontal cortex intervention. Participants receive 20 sham sessions during a single day, with session onsets separated by approximately 30 minutes.

Primary Outcomes

  • Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 4 (Baseline and 1, 2, 3, and 4 weeks after the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-08
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 69 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mclean Hospital
Contact Information
Study Contact:
Hakjoo Kim Kim, Ph.D.
979-777-0679
khj213@gmail.com
Hakjoo Kim, PhD
617-855-4203
hkim128@mclean.harvard.edu
McLean Hospital
Hakjoo Kim, PhD
McLean Hospital
Interventions
  • Device: Precuneus-targeted continuous theta-burst stimulation — Active continuous theta-burst stimulation is delivered to the Pz location of the international 10-20 EEG system to target the precuneus. Stimulation is administered with a double-cone coil at 80% of the participant's resting motor threshold. Each session consists of 600 pulses delivered over approximately 40 seconds. Participants receive 20 sessions during a single day, for a total of 12,000 pulses, with session onsets separated by approximately 30 minutes. If 80% of resting motor threshold is not tolerated, the intensity may be reduced to the highest tolerable level.
  • Device: Left dorsolateral prefrontal cortex intermittent theta-burst stimulation — Active intermittent theta-burst stimulation is delivered to the left dorsolateral prefrontal cortex. The stimulation target is identified using the Beam F3 method. Stimulation is administered with a figure-of-eight coil at 80% of the participant's resting motor threshold. Each session consists of 600 pulses delivered over approximately 3 minutes. Participants receive 20 sessions during a single day, for a total of 12,000 pulses, with session onsets separated by approximately 30 minutes. If 80% of resting motor threshold is not tolerated, the intensity may be reduced to the highest tolerable level.
  • Device: Sham transcranial magnetic stimulation — Sham transcranial magnetic stimulation is administered at the left dorsolateral prefrontal cortex location identified using the Beam F3 method. A figure-of-eight coil is inverted so that the active surface faces away from the scalp. The stimulator is operated at 80% of the participant's resting motor threshold using the same intermittent theta-burst timing and approximate session duration as the active left dorsolateral prefrontal cortex intervention. Participants receive 20 sham sessions during a single day, with session onsets separated by approximately 30 minutes.
Study Locations (1 sites)
McLean Hospital, Belmont, Massachusetts 02478 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older. * Able to speak, read, and understand English sufficiently to complete the study assessments and provide informed consent independently. * Diagnosis of major depressive disorder according to DSM-5-TR criteria, confirmed by a qualified physician. * Treatment-resistant depression, defined as an inadequate response to at least two adequate trials of antidepressant pharmacotherapy. * Patient Health Questionnaire-9 (PHQ-9) total score of 10 or higher. Exclusion Criteria: * Any condition identified through TMS safety screening that, in the judgment of a study physician, presents an unacceptable safety risk for TMS. Such conditions may include: * A history of a serious adverse reaction during TMS treatment. * A history of seizure. * A history of stroke. * A history of serious head injury or neurosurgery. * Metal in the head outside the mouth, such as shrapnel, surgical clips, or metal fragments. * An implanted device, such as a cardiac pacemaker, cochlear implant, medical pump, or intracardiac line. * Frequent or severe headaches. * Another brain-related condition or an illness that caused brain injury. * A family history of epilepsy. * Permanent tattoos on the head or neck. * Current recreational drug use. * Current pregnancy or possible pregnancy. * Use of a medication or combination of medications, a recent medication change, or medication withdrawal that, in the judgment of a study physician, presents an unacceptable safety risk, including a clinically significant increase in seizure risk. * Current or lifetime diagnosis of bipolar I disorder, bipolar II disorder, a schizophrenia spectrum disorder, or another primary psychotic disorder. * Active suicidal ideation with intent or plan requiring immediate clinical intervention, or another acute safety concern that cannot be safely managed within the study.
Conditions Anxiety Disorders, Depressive Disorder
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial (RCT) aims to compare the effectiveness of Islamic-Oriented Ericksonian Hypnotherapy (IEH) and Standard Ericksonian Hypnotherapy (SEH) in reducing symptoms of anxiety and depression. The study will enroll 90 participants with mild to moderate anxiety and depression, who will be randomly assigned to one of three groups: (1) IEH intervention, (2) SEH intervention, or (3) control group (no intervention). Participants in the intervention groups will receive 12 weekly hypnotherapy sessions, each lasting 60 minutes. The primary outcomes include changes in Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI) scores from baseline to post-intervention and at a 4-week follow-up. The study will also assess whether religious belief levels moderate the effects of the intervention using the OK-Religious Attitude Scale. Data collection will be performed at Istanbul Nişantaşı University, and ethical approval has been obtained.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Islamic-Oriented Ericksonian Hypnotherapy (IEH) — This intervention involves 12 weekly sessions (60 minutes each) of Ericksonian hypnotherapy integrated with Islamic religious elements. Sessions incorporate: Quranic metaphors and Islamic imagery Spiritual affirmations to enhance relaxation and emotional regulation Faith-based guided hypnosis adapted to cultural and religious beliefs Techniques such as indirect suggestions, therapeutic storytelling, and guided imagery The intervention is designed for Muslim participants with mild to moderate anxiety and depression.
  • Behavioral: Standard Ericksonian Hypnotherapy (SEH) — Participants receive 12 weekly sessions (60 minutes each) of standard Ericksonian hypnotherapy, which includes: Metaphorical storytelling and guided imagery Indirect hypnotic suggestions to promote psychological flexibility Relaxation techniques to reduce anxiety and depressive symptoms Unlike the Islamic-Oriented Hypnotherapy (IEH), this intervention does not integrate religious or faith-based elements.

Primary Outcomes

  • Beck Depression Inventory-II (BDI-II) (Baseline, Week 12 (post-intervention), Week 16 (follow-up))
  • Beck Anxiety Inventory (BAI) (Baseline, Week 12, Week 16)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-15
Completion: 2025-08-15
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Istanbul Nisantasi University
Principal Investigators:
  • Metin Çınaroğlu, Phd (PRINCIPAL_INVESTIGATOR) - Istanbul Nisantasi Universitesi
Contact Information
Study Contact:
Metin Çınaroğlu, Phd
+905324732070
metin.cinaroglu@nisantasi.edu.tr
Gözde Mert, Phd
+905359403399
gozde.mert@nisantasi.edu.tr
Metin Çınaroğlu, Phd
05324732070
metincinaroglu@gmail.com
İstanbul Nişantaşı University
Interventions
  • Behavioral: Islamic-Oriented Ericksonian Hypnotherapy (IEH) — This intervention involves 12 weekly sessions (60 minutes each) of Ericksonian hypnotherapy integrated with Islamic religious elements. Sessions incorporate: Quranic metaphors and Islamic imagery Spiritual affirmations to enhance relaxation and emotional regulation Faith-based guided hypnosis adapted to cultural and religious beliefs Techniques such as indirect suggestions, therapeutic storytelling, and guided imagery The intervention is designed for Muslim participants with mild to moderate anxiety and depression.
  • Behavioral: Standard Ericksonian Hypnotherapy (SEH) — Participants receive 12 weekly sessions (60 minutes each) of standard Ericksonian hypnotherapy, which includes: Metaphorical storytelling and guided imagery Indirect hypnotic suggestions to promote psychological flexibility Relaxation techniques to reduce anxiety and depressive symptoms Unlike the Islamic-Oriented Hypnotherapy (IEH), this intervention does not integrate religious or faith-based elements.
Study Locations (1 sites)
İstanbul Nişantaşı University, Istanbul, 34277 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Muslim individuals aged 18-65 years. * Mild to moderate anxiety and/or depression symptoms (assessed via Beck * Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI)). * No formal psychiatric diagnosis but experiencing psychological distress. * High religious belief levels, assessed via OK-Religious Attitude Scale. * Not currently receiving psychotherapy or psychotropic medication. * Ability to give informed consent and complete the study requirements. Exclusion Criteria: * Severe psychiatric disorders (schizophrenia, bipolar disorder, severe MDD). * Current use of psychotropic medication or undergoing psychotherapy. * History of substance abuse or dependence. * Diagnosed dissociative disorders (contraindications for hypnosis). * Cognitive impairment affecting comprehension of intervention. * Severe medical conditions that may interfere with participation.
Conditions Postoperative Complications, Respiratory...
Phase PHASE4
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Remimazolam — Remimazolam
  • Drug: Propofol — Propofol dose reduction ratio

Primary Outcomes

  • Dose change (Perioperatively (during upper gastrointestinal endoscopy))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-02-12
Completion: 2026-12-31
Eligibility
Age: 20 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kaohsiung Veterans General Hospital.
Principal Investigators:
  • CHIA-HAO YANG, M.D (PRINCIPAL_INVESTIGATOR) - employe
  • Tzung-Jim Tsai, M.D (PRINCIPAL_INVESTIGATOR) - employe
Contact Information
Study Contact:
Yuan-Yi Chia, M.D
886-7-342-2121
yychia@vghks.gov.tw
Chen-Hsiu Chen, Ph.D
886-7-342-2121
chschen@vghks.gov.tw
Yuan-Yi Chia, Bachelor
886-7-342-2121
yychia@isca.vghks.gov.tw
Kaohsiung Veterans General Hospital
Interventions
  • Drug: Remimazolam — Remimazolam
  • Drug: Propofol — Propofol dose reduction ratio
Study Locations (1 sites)
Kaohsiung Veterans General Hospital, Kaohsiung City, 81362 Taiwan
Eligibility Criteria
Inclusion Criteria: * Subjects are between 20-80 years old. * Anesthesiologists rated ASA as between I and III. * Patients undergoing upper gastrointestinal endoscopic examination or therapy. Exclusion Criteria: * Allergy to Propofol, Remimazolam, or opioid medications. * Emergency surgery. * Pregnancy. * History of malignant hyperthermia. * Impaired liver or kidney function. * Airway difficulties due to pharyngeal tumors. * Refusal to participate.